Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting.
We undertook this study to investigate whether there is an association between circulating oxidized low-density lipoproteins (OxLDLs) and outcome after coronary stenting. The study included 687 patients with coronary artery disease who underwent coronary stenting. Oxidized low-density lipoproteins were measured before coronary angiography. The median of OxLDL concentrations was 67.7 U/L. Patients were divided into 2 groups: the group with OxLDL levels < median (low OxLDL group, n = 345) and the group with OxLDL levels > or = median (high OxLDL group, n = 342). The combined incidence of major adverse cardiac events (death, myocardial infarction, and target vessel revascularization) was the primary end point. Angiographic restenosis was also evaluated. The combined incidence of death, myocardial infarction, and target vessel revascularization was 27.2% (n = 94) in the low OxLDL group and 25.4% (n = 87) in the high OxLDL group (OR .92, 95% CI 0.68-1.23, P = .59). At 6-month angiography, restenosis was found in 28.1% of the patients (n = 74) in the low OxLDL group and in 24.2% of the patients (n = 61) in the high OxLDL group. (P = .31). Our study shows no association between circulating levels of OxLDL and restenosis or other adverse events in patients with coronary artery disease after coronary stenting.